Meeting
2023 ASCO Annual Meeting
Clinico-molecular characteristics associated with outcomes in breast cancer patients treated with CDK4/6 inhibitors: Results from the AURORA Molecular Screening Initiative.
Authors
Elisa Agostinetto
Institut Jules Bordet and Université Libre de Bruxelles (U.L.B), Brussels, Belgium
Elisa Agostinetto , Christos Sotiriou , Michail Ignatiadis , Thayane Antoniolli Crestani , David Venet , Svitlana Tyekucheva , Alexandre Irrthum , Jose A. Seoane , Martine J. Piccart-Gebhart , David A. Cameron , Susan Knox , CRISTINA EMILIA ROTARU , Dario Romagnoli , Gabriele Zoppoli , Philippe Georges Aftimos , Mafalda Oliveira , Meredith M. Regan , Luca Malorni , Matteo Benelli , Florentine Hilbers
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT02102165
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1019)
DOI
10.1200/JCO.2023.41.16_suppl.1019
Abstract #
1019
Poster Bd #
240
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2− BC).
First Author: Pamela N. Munster
Poster
2022 ASCO Annual Meeting
ARV-471, an estrogen receptor (ER) PROTAC degrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.
First Author: Erika P. Hamilton
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye
Poster
2020 ASCO Virtual Scientific Program
Detection of actionable gene mutations in breast cancer by amplicon-based next-generation sequencing liquid biopsy.
First Author: Jing Shan Lim